All articles by Vidya Sagar Maddela
Vidya Sagar Maddela
US FDA approves Boehringer’s Hernexeos for HER2-positive NSCLC
Hernexeos, a tyrosine kinase inhibitor that selectively targets HER2, is the first oral targeted therapy approved for HER2-mutant advanced NSCLC.
CureVac, GSK settle mRNA patent litigation with Pfizer, BioNTech
The settlement involves a combined payment of $740m to CureVac and GSK, alongside single-digit royalties on US sales of Covid-19 vaccines.
XtalPi and DoveTree enter $6bn AI drug discovery partnership
XtalPi will leverage its AI and robotics expertise, while DoveTree will its biological insights, and hold exclusive global rights to therapeutics from the partnership.
Jazz secures FDA approval for Modeyso to treat rare brain tumour
Modeyso is a small molecule that acts as a protease activator and dopamine receptor inhibitor to induce apoptosis and alter mitochondrial metabolism.
SERB Pharma to acquire Y-mAbs Therapeutics for $412m
The acquisition will enhance SERB’s portfolio in rare diseases and medical emergencies, strengthening its position in the global pharmaceutical market.
SOPHiA, AstraZeneca expand AI collaboration for breast cancer
The collaboration will leverage SOPHiA’s AI Factories to generate evidence on the efficacy and real-world impact of breast cancer therapies.
Minaris Advanced Therapies opens new GMP facility in Germany
The new facility, located in Taufkirchen, aims to strengthen Minaris’ role in advancing cell and gene therapies from concept to commercialisation.
Turbine, Merck collaborate on cancer treatment development
The collaboration aims to identify novel dependencies in the specified cancer patient populations, potentially leading to discovery of new treatment options.
LENZ secures FDA approval for VIZZ to treat presbyopia
VIZZ works by contracting the iris sphincter muscle, creating a pinhole effect that extends the depth of focus, thereby improving vision.
Madrigal, CSPC sign licensing agreement for oral GLP-1 agonist
CSPC will receive an upfront payment of $120m and could earn up to $2bn in milestone payments, alongside royalties on net sales.